Lisata Therapeutics Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more
Lisata Therapeutics Inc. (LSTA) - Net Assets
Latest net assets as of September 2025: $17.12 Million USD
Based on the latest financial reports, Lisata Therapeutics Inc. (LSTA) has net assets worth $17.12 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.76 Million) and total liabilities ($4.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $17.12 Million |
| % of Total Assets | 78.68% |
| Annual Growth Rate | N/A |
| 5-Year Change | -9.07% |
| 10-Year Change | 25.91% |
| Growth Volatility | 1470.54 |
Lisata Therapeutics Inc. - Net Assets Trend (1990–2024)
This chart illustrates how Lisata Therapeutics Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lisata Therapeutics Inc. (1990–2024)
The table below shows the annual net assets of Lisata Therapeutics Inc. from 1990 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $29.32 Million | -38.79% |
| 2023-12-31 | $47.89 Million | -27.79% |
| 2022-12-31 | $66.32 Million | -27.91% |
| 2021-12-31 | $92.00 Million | +185.34% |
| 2020-12-31 | $32.24 Million | +56.87% |
| 2019-12-31 | $20.55 Million | -45.12% |
| 2018-12-31 | $37.45 Million | -25.38% |
| 2017-12-31 | $50.19 Million | +1134.23% |
| 2016-12-31 | $4.07 Million | -82.54% |
| 2015-12-31 | $23.28 Million | -59.91% |
| 2014-12-31 | $58.07 Million | -6.37% |
| 2013-12-31 | $62.03 Million | +88.99% |
| 2012-12-31 | $32.82 Million | -59.04% |
| 2011-12-31 | $80.13 Million | -7.35% |
| 2010-12-31 | $86.49 Million | +45.15% |
| 2009-12-31 | $59.59 Million | +6803.22% |
| 2008-12-31 | $863.18K | -73.97% |
| 2007-12-31 | $3.32 Million | +1035.27% |
| 2006-12-31 | $292.11K | +116.07% |
| 2005-12-31 | $-1.82 Million | +5.91% |
| 2004-12-31 | $-1.93 Million | -28.55% |
| 2003-12-31 | $-1.50 Million | -82.40% |
| 2002-12-31 | $-823.89K | -320.45% |
| 2001-12-31 | $373.73K | -88.06% |
| 2000-12-31 | $3.13 Million | -20.17% |
| 1999-12-31 | $3.92 Million | +1374.31% |
| 1998-12-31 | $-307.81K | +52.77% |
| 1996-12-31 | $-651.71K | -104.23% |
| 1995-12-31 | $-319.11K | +89.00% |
| 1994-12-31 | $-2.90 Million | -- |
| 1993-12-31 | $0.00 | -- |
| 1990-12-31 | $-700.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lisata Therapeutics Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 53516600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.03% |
| Other Comprehensive Income | $-81.00K | -0.27% |
| Other Components | $577.71 Million | 1953.64% |
| Total Equity | $29.57 Million | 100.00% |
Lisata Therapeutics Inc. Competitors by Market Cap
The table below lists competitors of Lisata Therapeutics Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PT Wintermar Offshore Marine Tbk
F:W6O
|
$35.40 Million |
|
GUNOSY INC.
F:6GU
|
$35.42 Million |
|
PRICELINE GROUP (PCE1.SG)
STU:PCE1
|
$35.43 Million |
|
Caladrius Biosciences Inc.
LSE:0HS8
|
$35.46 Million |
|
Gulshan Polyols Limited
NSE:GULPOLY
|
$35.39 Million |
|
Mcleod Russel India Limited
NSE:MCLEODRUSS
|
$35.38 Million |
|
Agile Content SA
MC:AGIL
|
$35.38 Million |
|
Advance Materials Corporation
TWO:3585
|
$35.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lisata Therapeutics Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 48,148,000 to 29,571,000, a change of -18,577,000 (-38.6%).
- Net loss of 19,985,000 reduced equity.
- New share issuances of 68,000 increased equity.
- Other comprehensive income decreased equity by 39,000.
- Other factors increased equity by 1,379,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.98 Million | -67.58% |
| Share Issuances | $68.00K | +0.23% |
| Other Comprehensive Income | $-39.00K | -0.13% |
| Other Changes | $1.38 Million | +4.66% |
| Total Change | $- | -38.58% |
Book Value vs Market Value Analysis
This analysis compares Lisata Therapeutics Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.41x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1990-12-31 | $-2489.63 | $5.01 | x |
| 1993-12-31 | $-2074.69 | $5.01 | x |
| 1994-12-31 | $-12033.20 | $5.01 | x |
| 1995-12-31 | $-19944.06 | $5.01 | x |
| 1996-12-31 | $-40731.81 | $5.01 | x |
| 1998-12-31 | $-19237.94 | $5.01 | x |
| 1999-12-31 | $47257.90 | $5.01 | x |
| 2000-12-31 | $21155.94 | $5.01 | x |
| 2001-12-31 | $2525.22 | $5.01 | x |
| 2002-12-31 | $-5529.50 | $5.01 | x |
| 2003-12-31 | $-8587.28 | $5.01 | x |
| 2004-12-31 | $-8904.30 | $5.01 | x |
| 2005-12-31 | $-5477.45 | $5.01 | x |
| 2006-12-31 | $210.91 | $5.01 | x |
| 2007-12-31 | $1514.94 | $5.01 | x |
| 2008-12-31 | $213.82 | $5.01 | x |
| 2009-12-31 | $2857.48 | $5.01 | x |
| 2010-12-31 | $1413.67 | $5.01 | x |
| 2011-12-31 | $1050.12 | $5.01 | x |
| 2012-12-31 | $359.53 | $5.01 | x |
| 2013-12-31 | $457.72 | $5.01 | x |
| 2014-12-31 | $267.96 | $5.01 | x |
| 2015-12-31 | $73.33 | $5.01 | x |
| 2016-12-31 | $11.19 | $5.01 | x |
| 2017-12-31 | $84.47 | $5.01 | x |
| 2018-12-31 | $58.41 | $5.01 | x |
| 2019-12-31 | $30.24 | $5.01 | x |
| 2020-12-31 | $31.58 | $5.01 | x |
| 2021-12-31 | $25.01 | $5.01 | x |
| 2022-12-31 | $12.85 | $5.01 | x |
| 2023-12-31 | $5.96 | $5.01 | x |
| 2024-12-31 | $3.55 | $5.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lisata Therapeutics Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -67.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1998.50%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.18x
- Recent ROE (-67.58%) is above the historical average (-193.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1990 | 0.00% | -60.22% | 1.36x | 0.00x | $-2.65 Million |
| 1994 | 0.00% | -16.01% | 2.15x | 0.00x | $-3.08 Million |
| 1995 | 0.00% | 0.00% | 0.00x | 0.00x | $1.74 Million |
| 1996 | 0.00% | 0.00% | 0.00x | 0.00x | $-267.43K |
| 1998 | 0.00% | 0.00% | 0.00x | 0.00x | $-302.22K |
| 1999 | -28.36% | -8653.62% | 0.00x | 1.32x | $-1.50 Million |
| 2000 | -64.74% | -381.19% | 0.12x | 1.47x | $-2.34 Million |
| 2001 | -543.97% | -1892.10% | 0.06x | 4.91x | $-2.07 Million |
| 2002 | 0.00% | -1425.77% | 0.07x | 0.00x | $-1.08 Million |
| 2003 | 0.00% | -1615.52% | 0.21x | 0.00x | $-893.87K |
| 2004 | 0.00% | -3600.36% | 0.49x | 0.00x | $-1.56 Million |
| 2005 | 0.00% | -4948.78% | 0.05x | 0.00x | $-1.56 Million |
| 2006 | -2071.52% | -13233.75% | 0.04x | 4.09x | $-6.08 Million |
| 2007 | -314.98% | -4508.89% | 0.06x | 1.14x | $-10.78 Million |
| 2008 | -1070.71% | -11062.92% | 0.05x | 2.11x | $-9.33 Million |
| 2009 | -105.53% | -226.29% | 0.11x | 4.28x | $-28.65 Million |
| 2010 | -47.90% | -33.38% | 0.49x | 2.94x | $-28.17 Million |
| 2011 | -75.99% | -469.00% | 0.06x | 2.50x | $-53.34 Million |
| 2012 | -165.12% | -382.29% | 0.26x | 1.64x | $-58.10 Million |
| 2013 | -62.33% | -265.74% | 0.16x | 1.44x | $-45.24 Million |
| 2014 | -93.78% | -305.89% | 0.14x | 2.16x | $-60.72 Million |
| 2015 | -341.10% | -359.69% | 0.39x | 2.41x | $-83.26 Million |
| 2016 | -668.64% | -92.55% | 0.68x | 10.61x | $-33.14 Million |
| 2017 | 45.50% | 0.00% | 0.00x | 1.25x | $17.93 Million |
| 2018 | -42.85% | 0.00% | 0.00x | 1.18x | $-19.94 Million |
| 2019 | -96.57% | 0.00% | 0.00x | 1.30x | $-22.18 Million |
| 2020 | -25.08% | 0.00% | 0.00x | 1.11x | $-11.40 Million |
| 2021 | -29.77% | 0.00% | 0.00x | 1.05x | $-36.69 Million |
| 2022 | -81.45% | -44.68% | 1.66x | 1.10x | $-60.88 Million |
| 2023 | -43.28% | 0.00% | 0.00x | 1.14x | $-25.65 Million |
| 2024 | -67.58% | -1998.50% | 0.03x | 1.18x | $-22.94 Million |
Industry Comparison
This section compares Lisata Therapeutics Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lisata Therapeutics Inc. (LSTA) | $17.12 Million | 0.00% | 0.27x | $35.39 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |